Valuation check: SNDX's profit margin is -72.38%, below the Healthcare sector average of 17.63%.
Get informed when a big investor buys or sells
+ FollowAs of Sep 2026
Trailing 12 months ending Sep 2026
The latest profit margin for SNDX is -72.38% as of September 2026. That compares with -279.31% in the prior-year period — up 74.1% year over year. That is below the Healthcare sector average of 17.63%. Investors often review this figure alongside Syndax Pharmaceuticals's historical trend and sector peers before judging valuation or financial health.
Over the past year, SNDX's profit margin moved from -279.31% to -72.38% — a 74.1% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Syndax Pharmaceuticals's valuation or profitability profile.
Against Healthcare companies, SNDX currently prints -72.38% for profit margin, while the sector average sits near 17.63%. That is roughly 510.6% below the sector mean. Large gaps often invite a closer look at Syndax Pharmaceuticals's growth, margins, and balance sheet.
Profit Margin shows how effectively Syndax Pharmaceuticals converts resources into returns. At -72.38%, SNDX may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -279.31% in the prior-year period — up 74.1% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.
After noting SNDX's profit margin (-72.38%), review year-over-year change from -279.31%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.